Background and Purpose-Whether patients with small perfusion lesions benefit from thrombolysis remains an uncertainty.
M
inor stroke often poses a dilemma for decision-making for thrombolysis. American Heart Association guidelines state that intravenous alteplase may be beneficial for mild stroke cases when judged as potentially disabling. 1 Meta-analysis of individual patient data from randomized trials also showing that minor stroke patients (National Institutes of Health Stroke Scale score [NIHSS] ≤4) treated with alteplase were more likely to have excellent outcome than those untreated. 2 However, a pilot survey provided evidence that an NIHSS score of 2 was identified as a potential equipoise point, with the least consensus on thrombolysis decision. Moreover, there were various factors affecting clinician's treatment decision, and NIHSS score was not the only determinant. 3 In the past decade, perfusion imaging has been demonstrated to be helpful in thrombolysis decision-making. However, a majority of clinical trials have primarily focused on patients with comparatively large lesions. For example, DEFUSE-2 (The Diffusion and Perfusion Imaging Evaluation for Understanding Stroke Evolution 2) and SWIFT-PRIME (Solitaire With the Intention for Thrombectomy as Primary Endovascular Treatment for Acute Ischemic Stroke) excluded patients with small perfusion lesions (<15 mL). 4 Notably, a recent study focusing on acute ischemic stroke (AIS) patients with small perfusion lesions (<15 mL) demonstrated that these patients had no observable benefit from thrombolysis, and alteplase-treated patients were even less likely to have excellent outcome compared with those untreated patients. 5 However, another study suggested alteplase treatment contributed to significant improvement in functional outcome for minor stroke patients (NIHSS ≤3) with larger volumes of penumbra. 6 It seems that not all minor stroke patients will benefit from thrombolysis, but at least some of them will deteriorate if timely reperfusion does
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November 2018 not occur. The challenge is to identify which minor stroke should be aggressively treated. Till now, most ischemic stroke studies incorporating imaging analyses have focused on the overall extent of hypoperfusion and infarct core lesions for decision-making of thrombolysis. However, it is known that lesion localization can play a critical role in longer-term functional outcome. 7, 8 The corticospinal tract (CST) lesion load in AIS patients has been shown to predict poststroke motor outcomes at 3-month. 9 Salvage of the CST via reperfusion was associated with improved outcome, independent of overall salvage of ischemic tissue in anterior circulation stroke. 10 Therefore, we hypothesized that patients with a small perfusion lesion involving the CST might have worse clinical outcomes than those with a small perfusion lesion not involving the CST, and the benefit of thrombolysis may be various in different CST lesion pattern groups. We thus assessed CST perfusion and infarction, respectively, in AIS patients with perfusion lesions <15 mL, and aimed to evaluate the benefit and risk of thrombolysis in different CST lesion pattern groups. In addition, to clarify the effect of CST lesion on outcome, we also investigate (1) whether hypoperfusion and infarction involving CST relate to poor outcome; (2) relationships among CST hypoperfusion/infarction, thrombolysis, and outcome; and (3) relationships among non-CST hypoperfusion/infarction, thrombolysis, and outcome.
Methods
The data that support the findings of this study are available from the corresponding author on reasonable request.
Patients
Clinical and imaging information from AIS patients who underwent multimodal computed tomography (CT) perfusion (CTP) within 12 hours of symptom onset at 7 centers in Australia, China, and Canada between 2011 and 2017 were prospectively collected for the International Stroke Perfusion Imaging Registry. These sites were involved in the registry as they routinely perform multimodal CTP before reperfusion treatment. Imaging acquisition parameters were standardized across sites as part of the registry design. Detailed register information of International Stroke Perfusion Imaging Registry has been described in our previous study. 5 Clinical and imaging information from AIS patients who underwent multimodal magnetic resonance (MR) imaging, including MR perfusion (MRP) within 12 hours of symptom onset between 2011 and 2017 were also prospectively collected at our single center, which was registered as CIPPIS (Comparison Influence to Prognosis of CTP and MRP in AIS Patients) (http://www.clinicaltrials.gov. Unique identifier: NCT03367286).
Eligible patients were treated with intravenous thrombolysis according to local guidelines and the clinical judgment of the treating physician, but not based on perfusion image. Written informed consent was obtained from all participants. The International Stroke Perfusion Imaging Registry study was approved by the local ethics committees in accord with Australian National Health and Medical Research Council guidelines. The study was also approved by our local human ethics committees.
Specifically for this study, we included patients who (1) underwent CTP or MRP within 4.5 hours of symptom onset at baseline; (2) had a perfusion lesion <15 mL at baseline; (3) underwent CT or MR at 24 hours; (4) had complete follow-up at 90 days. We excluded patients who (1) had poor image quality because of movement artifacts which were assessed by an experienced neuroradiologist (Dr Minming Zhang); (2) received mechanical thrombectomy. Figure I in the online-only Data Supplement shows the flowchart.
Image Analysis and Classification of Patients
All perfusion images and apparent diffusion coefficient images were retrospectively postprocessed on commercial software (MIStar; Apollo Medical Imaging Technology, Melbourne, Australia). The time to maximum of tissue residue function map was produced using standard singular value deconvolution without delay-correction. The arterial input function was automatically selected, which should be a global arterial input function from normal artery. Previously validated thresholds were applied to identify the areas of hypoperfusion (the time to maximum of tissue residue function >6 s) and infarct core (relative cerebral blood flow <30% on CT or apparent diffusion coefficient <620×10 -6 mm 2 /s on MRI). 11, 12 One experienced neurologist (Dr Yan) and another neuroradiologist (Dr Minming Zhang) who were blinded to all other imaging and clinical data checked and corrected the hypoperfusion and infarct lesions manually, including 2 steps: (1) correction of nonparenchymal areas, including ventricles and leptomeninges which was mislabeled as hypoperfusion or infarct lesion; (2) correction of cerebral parenchymal areas in the unaffected hemisphere which was mislabeled as hypoperfusion or infarct lesion. Then 2 experienced neurologists (Drs Zhou and R. Zhang) blinded to clinical data reviewed images for the assessment of presence or absence of CST hypoperfusion and infarction independently, and the inconsistency data were reviewed by another experienced neurologist (Dr Hu). Dr Zhou assessed the data of all patients twice at an interval of 3 months apart. First, the templates of different layers demonstrating the CST, including posterior limb of internal capsule, upper extent of corona radiata, and brain stem were derived from Matsui and Hirano atlas and atlas of MRI and CT. 13, 14 Using these templates, we identified the site of CST in the corresponding layers on postprocessed CT or MR images, and then identified whether hypoperfusion or infarction involved CST areas. CST hypoperfusion or CST infarction was defined as hypoperfusion or infarction involving CST areas, respectively. Non-CST hypoperfusion or non-CST infarction was defined as hypoperfusion or infarction involving areas other than CST, respectively. Patients were then divided into 3 groups: (1) no CST lesion, including patients with non-CST infarction, patients with non-CST hypoperfusion without non-CST infarction, and patients with no lesion; (2) CST hypoperfusion with no CST infarction; and (3) CST infarction.
The NIHSS was collected at baseline, and the modified Rankin Scale score (mRS) was collected at 90 days after stroke onset. The proximal arterial occlusion of Willis circle was assessed on baseline MR angiography or CT angiography. Intracerebral hemorrhage (ICH) and symptomatic ICH (sICH) were assessed on follow-up 24-hour MR or CT images according to ECASS III trial (European Cooperative Acute Stroke Study). 15 The primary outcome was mRS 0 to 1 at 90 days.
Multimodal CT and MR Protocol and statistical analysis methods are provided in the online-only Data Supplement.
Results

Subject Characteristics
Of 2654 patients who underwent CTP or MRP within 12 hours of symptom onset, 407 had CTP or MRP within 4.5 hours after onset and who had a perfusion lesion <15 mL were included. Among these, 243 (59.7%) patients were treated with alteplase. The mean age was 68.2±13.7 years, and 166 (40.8%) were female. Baseline median NIHSS score was 5.0 (interquartile range, 2.0-8.0), baseline hypoperfusion volume was 3.6±4.6 mL, baseline infarct volume was 1.4±2.5 mL, and 90-day mRS 0-1 occurred in 312 (76.7%) of patients. Compared with the untreated group, the alteplase-treated group had higher baseline NIHSS, shorter onset to image time (OIT), and were more likely have CST hypoperfusion and infarction (Table 1 ; all P<0.05).
Relationship Among Thrombolysis, Hypoperfusion/Infarction, and Outcome
Compared with patients who had mRS 2 to 6 at 90 days, patients with mRS 0 to 1 were younger, had lower baseline NIHSS, and longer OIT, and were less likely to be treated with alteplase (Table I in the online-only Data Supplement; all P<0.1). Treatment of alteplase was an independent unfavorable factor for mRS 0 to 1 after adjusting for age, baseline NIHSS, and OIT with binary logistic regression (model 1 in Table 2 ; alteplase-treated 72.0% versus untreated 83.5%; odds ratio (OR), 0.541; 95% CI, 0.317-0.925; P=0.025). More patients in alteplase-treated group had ICH at 24 hours after adjusting for age, baseline NIHSS, and OIT with binary logistic regression (alteplase-treated 9.5% versus untreated 0.6%; OR, 19.364; 95% CI, 2.538-147.734; P=0.004). Three (1.2%) alteplase-treated patients had sICH, and no patients had sICH in untreated group.
Two hundred and seventy-nine (68.6%) patients had hypoperfusion, and 225 (55.3%) patients had infarction. Both the presence of hypoperfusion (model 2 in Table 2 ; P=0.238) and infarction (model 3 in Table 2 ; P=0.443) were not independent influencing factors for mRS 0 to 1 after adjusting for age, baseline NIHSS, OIT, and treatment of alteplase.
Relationship Between CST Hypoperfusion/ Infarction and Outcome
Excellent interrater reliability (κ=0.915) and intrarater reliability (κ=0.883) were seen in assessing the presence or absence of CST hypoperfusion and infarction.
In patients with hypoperfusion (n=279), compared with patients who had mRS 2 to 6 at 90 days, patients with mRS 0 to 1 were younger, had lower baseline NIHSS, and were less likely to have CST hypoperfusion and to be treated with alteplase (Table II in the online-only Data Supplement; all P<0.1). The presence of CST hypoperfusion was an independent unfavorable factor for mRS 0 to 1 after adjusting for age, baseline NIHSS, OIT, and treatment of alteplase (Table III in In patients with infarction (n=225), compared with patients who had mRS 2 to 6 at 90 days, patients with mRS 0 to 1 were younger, had lower baseline NIHSS, and were more likely to smoke, and were less likely to have CST infarction and to be treated with alteplase (Table IV in the online-only Data Supplement; all P<0.1). The presence of CST infarction was an independent unfavorable factor for mRS 0 to 1 after adjusting for age, smoking, baseline NIHSS, OIT, and treatment of alteplase (Table V in Relationship Among CST Hypoperfusion/ Infarction, Thrombolysis, and Outcome Treatment of alteplase×CST infarction was an independent unfavorable factor for mRS 0 to 1 after adjusting for age, baseline NIHSS, OIT, treatment of alteplase, and presence of CST infarction (model 4 in Table 2 ; OR, 0.028; 95% CI, 0.002-0.316; P=0.004).
Treatment of alteplase×CST hypoperfusion was not an independent influencing factor for mRS 0 to 1 after adjusting for age, baseline NIHSS, OIT, treatment of alteplase, and presence of CST hypoperfusion (model 5 in Table 2 ; P=0.941).
Treatment of alteplase×CST hypoperfusion without CST infarction was an independent favorable factor for mRS 0 to1 after adjusting for age, baseline NIHSS, OIT, treatment of alteplase, and presence of CST hypoperfusion without CST infarction (model 6 in Table 2 ; OR, 9.854; 95% CI, 2.474-39.242; P=0.001).
Relationship Among Non-CST Hypoperfusion/ Infarction, Thrombolysis, and Outcome
Most patients who had CST mismatch also had non-CST mismatch, so it is difficult for direct comparison of the effect of alteplase between mismatch areas in CST and non-CST areas and infarcts in CST and non-CST areas. Therefore, we further analyzed the effect of alteplase in patients with mismatch in non-CST areas and patients with infarcts in non-CST areas. 
Stroke
November 2018
Treatment of alteplase×non-CST infarction was not an independent influencing factor for mRS 0 to 1 after adjusting for age, baseline NIHSS, OIT, treatment of alteplase, and presence of non-CST infarction (model 1 in Table XII in the online-only Data Supplement; P=0.601).
Treatment of alteplase×non-CST hypoperfusion was not an independent influencing factor for mRS 0 to 1 after adjusting for age, baseline NIHSS, OIT, treatment of alteplase, and presence of non-CST hypoperfusion (model 2 in Table XII in the online-only Data Supplement; P=0.461).
Treatment of alteplase×non-CST hypoperfusion without non-CST infarction was not an independent influencing factor for mRS 0 to 1 after adjusting for age, baseline NIHSS, OIT, treatment of alteplase, and presence of non-CST hypoperfusion without non-CST infarction (model 3 in Table XII in 
Relationship Between Thrombolysis and Outcome in Different CST Lesion Groups
Patients were then divided into 3 groups. For patients with no CST lesion (n=304), 254 (83.6%) achieved mRS 0 to 1. Treatment of alteplase was not an independent influencing factor for mRS 0 to 1 (Tables 3 and 4 ; alteplase-treated 80.1% versus untreated 87.7%; P=0.258) after adjusting for age, smoking, baseline NIHSS, and OIT with binary logistic regression. Alteplase-treated patients were more likely to have ICH than untreated patients (11 [6.6%] versus 0; P=0.001). The rate of mRS 2 to 6 in ICH patients was 27.3% (3/11). Two (1.2%) alteplase-treated patients had sICH, and no patient had sICH in the untreated group.
For patients who had CST hypoperfusion with no CST infarction (n=58), 39 (67.2%) achieved mRS 0 to 1. Treatment of alteplase was an independent favorable factor for mRS 0 to 1 (Tables 3 and 4 ; alteplase-treated 75.6% versus untreated 47.1%; OR, 4.096; 95% CI, 1.031-16.272; P=0.045) after adjusting for age, baseline NIHSS, and OIT with binary logistic regression. Moreover, 5 (12.2%) alteplase-treated patients and 1 (5.9%) untreated patient were found with ICH, and no patients had sICH in either alteplase-treated or untreated groups.
In patients with CST infarction (n=45), 19 (42.2%) achieved mRS 0 to 1. Treatment of alteplase was an independent unfavorable factor for mRS 0 to 1 (Tables 3 and  4 ; alteplase-treated 30.6% versus untreated 88.9%; OR, In addition, we divided patients with no CST lesion (without CST hypoperfusion or CST infarction) into the following 3 subgroups: patients with no lesion (n=128), patients with non-CST hypoperfusion without non-CST infarction (n=28), and patients with non-CST infarction (n=148). We found that treatment of alteplase was not independent influencing factors for mRS 0 to 1 in no lesion group and non-CST infarction group (Tables XIII and XIV in Besides, 2 patients' ICH lesions affected CST. One had CST infarction at baseline, sICH at 24 hours, and mRS 6 at 90 days. Another had no CST lesion at baseline, no sICH at 24 hours, and mRS 1 at 90 days. Figures 1 and 2 show representative patients in the 3 groups. Figure II in the online-only Data Supplement shows the mRS distribution of alteplase-treated and untreated patients with different CST lesion patterns.
Discussion
In current study, the main finding was that among AIS patients eligible for alteplase therapy with small perfusion lesions (<15 mL), only patients who had CST hypoperfusion without CST infarction benefited from thrombolysis. We also found (1) both CST hypoperfusion and CST infarction were unfavorable for mRS 0 to 1, (2) treatment of alteplase×CST mismatch was favorable for mRS 0 to 1, and (3) treatment of alteplase×non-CST mismatch was not an independent influencing factor for mRS 0 to 1. These findings suggest that it is clinically important to focus on the CST lesion when considering thrombolysis for patients with small perfusion lesions (<15 mL).
CST is a major neural tract for motor function in human brain, and as such preservation of the CST is essential to maintain good motor function in patients with brain injury. 16 Previous studies have shown that the degree of CST infarction volume on diffusion weighted image at 2 to 7 days after stroke predicted 3-month motor function, 9 indicating that motor function injury related to CST infarction at acute phase is unlikely to recover. As the mismatch principle demonstrated in a previous study, baseline volume of ischemic core would approximate the final infarction volume in patients who achieve reperfusion, whereas baseline volume of hypoperfusion would predict the final infarction volume in nonreperfusers 17 ; we then specifically applied this principle to CST in our last study and demonstrated that hypoperfused CST tissue at baseline could be salvaged by timely reperfusion, whereas CST infarction tissue may not be salvageable. 10 Moreover, without reperfusion, hypoperfused CST tissues would progress into irreversible injury. Consistent with these results, our current findings further confirmed this mismatch principle of CST among AIS patients with small perfusion lesions (<15 mL) and highlight that thrombolysis is of benefit for those patients 
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with CST hypoperfusion but not CST infarction. In addition, our data revealed that mismatch was a good prognostic factor in CST but not in other areas for alteplase treatment. This might be because of the evaluation of prognosis with mRS, which is closely related to motor function. Thus, the deficits might not be assessed even though the hypoperfused tissues in other areas progressed into irreversible injury. Based on the 24-hour follow-up diffusion weighted image, we found that in more than half of cases, the hypoperfusion in the CST areas is completely reversible, which is different from previous opinion that reperfusion in terminal vascular territories, such as CST areas after 150 minutes (median OIT) of ischemia, was unlikely to preserve cerebral tissue from infarction in the absence of collateral circulation. 18 However, previous neuroanatomic studies and recent perfusion studies suggested that collateral blood flow compensation might be present between deep perforating arteries. 19, 20 In addition, fiber tracts were suggested to have greater ischemic tolerance than other regions. 21 It is thus interesting to confirm our finding in future and identify the , and penumbra (green area) and core (red areas) map (middle). The total volume of penumbra and infarct core, baseline National Institutes of Health Stroke Scale (NIHSS), and modified Rankin Scale (mRS) score at 90 d were listed on the right side. We chose the representative layers on which the lesions were most close to the corticospinal tract (CST). A, Two patients with no CST lesion at baseline, and both of them achieved 90-d mRS 0-1. B, Two patients with CST hypoperfusion with no CST infarction at baseline, and the alteplase-treated one achieved mRS 0, whereas the untreated one had mRS 3 at 90 d. C, Two patients with CST infarction at baseline, and both of them had 90-d mRS 2-6. changing patterns of hypoperfusion tissues of deep perforating arterial territories.
Importantly, our data revealed that patients either with CST infarction lesion or without any CST hypoperfusion lesion may not benefit from alteplase treatment. Indeed, despite relatively small strokes, it is notable that thrombolysis increased the rate of ICH in patients with either no CST lesion or CST infarction. This could be explained by the preclinical data, which showed that alteplase participated in the disruption of microvascular basal lamina, thereby causing the disruption of blood-brain barrier and edema formation. 22 Moreover, previous experiments have already demonstrated that alteplase itself could promote the direct neurotoxicity of tissues because early studies in knockout mice suggested that alteplase harmed neurons, being neurotoxic. 23, 24 Strengths of our analysis included that the assessment of CST hypoperfusion and infarction lesions was reliable, simple, and fast; therefore, the method could be easily applied Figure 2 . Representative examples of 6 patients who underwent magnetic resonance perfusion at baseline, including time to maximum of tissue residue function (Tmax) map (left), apparent diffusion coefficient (ADC) map (right), and penumbra (green area) and core (red areas) map (middle). The total volume of penumbra and infarct core, baseline National Institutes of Health Stroke Scale (NIHSS) and modified Rankin Scale (mRS) score at 90 d were listed on the right side. We chose the representative layers on which the lesions were most close to the corticospinal tract (CST). A, Two patients with no CST lesion at baseline, and both of them achieved 90-d mRS 0-1. B, Two patients with CST hypoperfusion with no CST infarction at baseline, and the alteplase-treated one achieved mRS 1 whereas the untreated one had mRS 4 at 90 d. C, Two patients with CST infarction at baseline, and both of them had 90-d mRS 2-6.
in the acute phase. Although our total findings are consistent with our previous study which showed that, for patients with small perfusion lesion (<15 mL), alteplase treatment might worsen the neurological outcome, 5 the novel finding is that we could still successfully select patients (CST hypoperfusion with no CST infarction) who might benefit from thrombolysis.
Limitations include the retrospective nature of the study (although the data were prospectively collected). It remains possible that an observational, nonrandomized design has influenced our results. Currently, it is only hypothesis-generating, and future prospective studies are needed to confirm our findings. Second, the identification of hypoperfusion and infarct lesions might be false positive, which are not infrequent in CTP studies, although corrections were done to avoid them. Because the hypoperfusion lesion might be reperfused, and the unaffected area might process to infarct lesion, the follow-up imaging can hardly confirm the lesion at baseline. Therefore, we may not avoid some false negative or stroke mimics in patients with no hypoperfusion or infarct lesion. Third, small lesions might not be assessed on perfusion images, which might also influence the clinical outcome. Fourth, the identification of CST site may be challenging, but we used standard templates, and the inter and intraobserver reliability was excellent. Fifth, in the current study, we took the data of MRP and CTP together. However, MRP is more sensitive to detect lesions than CTP, and the differentiation of hypoperfusion and infarction on CTP is not clear though k values are excellent. The different techniques and hypoperfusion/infarction assessment thus may lead to baseline imaging differences. Therefore, future studies are needed to confirm our results based on the same image mode. Finally, motor function is not the sole determinant of functional outcome, and other key abilities, such as language could be similarly studied in future studies.
Conclusions
In conclusion, this retrospective study found that among AIS patients with small perfusion lesions (<15 mL), only patients with CST hypoperfusion and no CST infarction lesion benefited from thrombolytic therapy, and patients with CST infarction or without any CST hypoperfusion lesion did not benefit from alteplase treatment.
